News for SciSparc Ltd. (SPRCY)

TEL AVIV, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the 'Company” or 'SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announces additional progress in connection with the proposed merger with AutoMax Motors Ltd., a leading vehicles importer and the exclusive importer of Anhui Jianghuai Automobile Group Corp., Ltd.-manufactured electric vehicles in Israel ('AutoMax”).

Vancouver, Canada, July 30, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ('Clearmind” or the 'Company'), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the filing of a new international patent application under the Patent Cooperation Treaty (PCT). The application covers its innovative combination therapy of MEAI (5-methoxy-2-aminoindane and N-Acylethanolamines) and Palmitoylethanolamide (PEA).

TEL AVIV, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ('Company' or 'SciSparc'), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) ('Clearmind”) has led to the filing of a new international patent application under the Patent Cooperation Treaty. The application covers its innovative combination therapy of 5-methoxy-2-aminoindane and N-Acylethanolamines (MEAI) and Palmitoylethanolamide (PEA).

Tel Aviv, July 22, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (”œSciSparc” or the ”œCompany”) ( SPRC), a specialty clinical-stage pharmaceutical company foc

SciSparc Ltd. (SPRC) regains compliance with Nasdaq's minimum bid price requirement. The company's shares maintained a closing bid price of $1.00 or hig

PR NewswireTORONTO and GLIL YAM, Israel, July 9, 2025 TORONTO and GLIL YAM, Israel, July 9, 2025 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company")

TEL AVIV, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. ( SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing

Clearmind Medicine (CMND) has reached a crucial milestone with the publication of its European patent application by the European Patent Office. This patent, id

Patent publication in Europe strengthens Clearmind's global IP position and advances strategic focus on addiction treatment Vancouver, Canada, May 12, 2025 (

\n SciSparc Ltd. (SPRC) collaborates with Clearmind Medicine Inc. on an innovative addiction treatment. The partnership focuses on a patent application in

SciSparc Ltd. (SPRC) has joined forces with Clearmind Medicine to file an international patent application for a novel treatment targeting eating disorders such

**media[605557]**

Vancouver, Canada, March 10, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. ( CMND), (FSE: CWY0) (”œClearmind” or the "Company"), a clinical-stage biote

TEL AVIV, Israel, March 10, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. ( SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company f

**media[555553]**

TEL AVIV, Israel, Feb. 27, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. ( SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company fo

Neve Yarak, Israel, Feb. 26, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc.\ ( NITO) (FSE:80W) (”œN2OFF” and the ”œCompany”), a clean tech company engaged in sust

February 14, 2025 (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces today's roundup of stocks to wat...

No Immediate Effect on Nasdaq Listing or Trading of the Company's Ordinary Shares TEL AVIV, Israel, Jan. 15, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. ( SPRC)